Colin Walsh, Director at Attovia Therapeutics, Inc. (ATTO), bought 585,000 shares at $21.00 ($10.3M) on 2026-08-05, disclosed to the SEC on 2026-08-13.
Director Colin Walsh purchased $1.79M of stock at $21.00, marking the largest insider purchase in the company's history and signaling strong conviction in the current valuation. This significant accumulation follows a recent insider buying cluster, suggesting that other insiders share this bullish outlook.
The stock is trading 15.69% below its 52-week high of $22.75 and has dropped 7.1% over the last 5 days, presenting a potential entry point for the recent insider buying.
1) The largest insider purchase in company history occurred on 2026-08-05; 2) A cluster of 3 other insiders bought shares in the last 30 days; 3) Insiders have a net buyer flow of 3.0 over the last 90 days.
The stock is currently trading 18.43% above its 52-week low of $16.20, indicating that the recent price drop may be a temporary correction rather than a sustained value opportunity.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $21.00 | 85,000 | $1.8M | 17.4% |
| 2 | $17.00 | 500,000 | $8.5M | 82.6% |
| Total | $17.58 avg | 585,000 | $10.3M | 100% |